Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-02-19

Clinical Trial Update: EPO Deep Tank in Dialysis Subjects [Phase 3]

View source ↗

Summary

Amgen completed a Phase 3 trial of an erythropoietin product in dialysis patients with chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Epogen (epoetin alfa)

Snippet

Sponsor: Amgen | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED